お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
988072

ポイントオブケア (POC) 診断・検査の市場動向・市場シェア・市場規模の予測 (2021-2028年):製品 (感染症・がんマーカー)・エンドユーザー (在宅医療・診療所)・地域別

Point Of Care Diagnostics & Testing Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Cancer Marker), By End-use (Home, Clinics), By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 140 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
ポイントオブケア (POC) 診断・検査の市場動向・市場シェア・市場規模の予測 (2021-2028年):製品 (感染症・がんマーカー)・エンドユーザー (在宅医療・診療所)・地域別
出版日: 2021年01月25日
発行: Grand View Research, Inc.
ページ情報: 英文 140 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のポイントオブケア (POC) 診断・検査の市場規模は予測期間中3.25%のCAGRで推移し、2028年には357億4000万米ドルの規模に成長すると予測されています。従来のラボテストの有益な代替手段であること、患者ケアの現場で重要な情報を提供でき、早期診断が可能となること、非侵襲・低侵襲POCデバイス、連続POCT、小型化技術などの台頭、遠隔患者モニタリングにおける遠隔医療の導入などの要因が同市場の成長を推進しています。

当レポートでは、世界のポイントオブケア (POC) 診断・検査の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、関連法規制、技術動向、市場規模の推移・予測、製品・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場動向・展望
  • 市場の分類・範囲
  • 親市場の見通し
  • 市場力学
  • 普及・成長の見通しマッピング
  • PEST分析・SWOT分析
  • ポーターのファイブフォース分析
  • 主な取引・戦略的提携
  • 市場参入戦略
  • 価格・コスト・マージンの分析
  • ユーザーの視点分析
  • 技術概要
  • 市場の影響力
  • 製品ポジショニング
  • 規制の枠組み:米国
  • 規制の枠組み:欧州
  • 規制の枠組み:日本

第4章 COVID-19:影響分析

第5章 競合分析

  • 主要企業・近年の展開・影響分析
  • 企業・競合上の分類
  • ベンダー情勢
  • 主要企業ランキング
  • 公開企業
  • 非公開企業
  • 新規参入事業者・新興事業者
  • 地域マッピング:公開企業・非公開企業

第6章 市場予測・動向分析:製品別

  • グルコース検査
  • Hb1ac検査
  • 凝固検査
  • 不妊治療検査
  • 感染症
  • 心臓マーカー
  • 甲状腺刺激ホルモン
  • 血液検査
  • プライマリーケアシステム
  • 分散型臨床化学検査
  • 便検査
  • 脂質検査
  • がんマーカー
  • 血液ガス/電解質
  • 外来化学検査
  • 薬物乱用試験
  • 尿検査

第7章 市場予測・動向分析:エンドユーザー別

  • 診療所
  • 病院
  • 在宅医療
  • 介護施設
  • ラボ

第8章 市場予測・動向分析:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Qiagen
    • Danaher Corporation
    • Becton Dickinson (BD)
    • Biomerieux SA
    • Abbott Laboratories
    • Siemens Healthcare AG
    • Zoetis, Inc.
    • Instrumentation Laboratory
    • Nova Biomedical
    • Trividia Health, Inc.
    • Quidel Corporation
    • Trinity Biotech
    • Sekisui Diagnostics
    • Orasure Technologies, Inc.
    • Nipro Corp.
    • Spectral Medical, Inc.
図表

List of Tables

  • 1. List of secondary sources
  • 2. Examples: CLIA waived tests
  • 3. North America diabetes prevalence (national prevalence %), 2013 & 2035
  • 4. Europe diabetes prevalence (national prevalence %), 2013 & 2035
  • 5. Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035
  • 6. Latin America Diabetes Prevalence (national prevalence %), 2013 & 2035
  • 7. MEA and Africa diabetes prevalence (national prevalence %), 2013 & 2035
  • 8. CIS diabetes prevalence (national prevalence %), 2013 & 2035
  • 9. Description of POC devices for detection of diseases through specific salivary biomarkers
  • 10. Methods used for the evaluation of diagnostic toolboxes
  • 11. List of companies operating in the COVID-19 Point of Care diagnostics market
  • 12. Abbott Healthcare: List of Wholesalers & Distributors
  • 13. North America point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 14. North America point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 15. The U.S. point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 16. The U.S. point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 17. Canada point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 18. Canada point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 19. Europe point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 20. Europe point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 21. Germany point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 22. Germany point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 23. The U.K. point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 24. The U.K. point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 25. National and international requirements for quality management of Point of Care testing in France
  • 26. France point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 27. France point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 28. Italy point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 29. Italy point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 30. Spain point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 31. Spain point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 32. Russia point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 33. Russia point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 34. Asia Pacific point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 35. asia Pacific point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 36. Japan point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 37. Japan point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 38. China point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 39. China point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 40. Some of the local glucose POC testing manufacturers in india
  • 41. India point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 42. India point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 43. Primary guidelines for glucose POC testing in Australia
  • 44. Australia point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 45. Australia point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 46. Korea point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 47. Korea point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 48. Latin America point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 49. Latin America point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 50. Brazil point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 51. Brazil point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 52. Mexico point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 53. Mexico point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 54. Middle East & Africa point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 55. Middle East & Africa point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 56. South Africa point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 57. South Africa point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)
  • 58. Saudi Arabia point of care (PoC) diagnostics market estimates and forecast, by product, 2017 - 2028 (USD Million)
  • 59. Saudi Arabia point of care (PoC) diagnostics market estimates and forecast, by end use, 2017 - 2028 (USD Million)

List of Figures

  • 1. Market research process
  • 2. Data triangulation techniques
  • 3. Primary research pattern
  • 4. Market revenue model
  • 5. POC segment penetration mapping
  • 6. Pricing analysis
  • 7. Market research approaches
  • 8. Value chain-based sizing & forecasting
  • 9. QFD modeling for market share assessment
  • 10. Market formulation & validation
  • 11. Market summary, 2020 (USD Million)
  • 12. Market trends & outlook
  • 13. Market segmentation & scope
  • 14. Parent market outlook
  • 15. Related/ancillary market outlook
  • 16. Point of care diagnostics market: Driver relevance analysis (Current & future impact)
  • 17. Shift in POC molecular diagnostic trends
  • 18. Global percentage of population, by age group, 2000 and 2050
  • 19. Population over the age of 65 years, by region, 2010 and 2050
  • 20. Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
  • 21. Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
  • 22. Point of care diagnostics market: Restraint relevance analysis (Current & future impact)
  • 23. Point of care diagnostics market: Challenge relevance analysis (Current & future impact)
  • 24. Point of care diagnostics market: Opportunity relevance analysis (Current & future impact)
  • 25. Accountable factors to ensure adequate accessibility of POC diagnostic solutions
  • 26. Penetration and growth prospect mapping
  • 27. Factors impacting market entry strategies
  • 28. Key market entry methods
  • 29. Consumption trends for POCT
  • 30. Product positioning analysis, 2020
  • 31. COVID-19 point of care (PoC) diagnostics market: Trend analysis
  • 32. COVID-19 Point of Care diagnostics: Technology landscape
  • 33. Recent Developments & Impact Analysis, by Key Market Participants
  • 34. Key market participants: Impact analysis, 2020
  • 35. Key market participants: Revenue-strategy mapping
  • 36. Company categorization
  • 37. Marketing channels
  • 38. Key customers
  • 39. Competitive Landscape POC Diagnostics - Major market participants
  • 40. Competitive dashboard analysis for public players
  • 41. Roche Distribution Presence
  • 42. instrumentation Laboratory (Werfen Group) Distribution Presence
  • 43. Abbott Laboratories Distribution Network Coverage
  • 44. Alere Distribution Presence
  • 45. Siemens Healthcare Distribution Presence
  • 46. Danaher Distribution Presence (Radiometer, HemoCue, and Beckman Coulter)
  • 47. Becton Dickinson Presence
  • 48. point of care (PoC) diagnostics market: Product outlook and key takeaways
  • 49. point of care (PoC) diagnostics market: Product movement analysis
  • 50. Glucose point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 51. Hb1Ac point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 52. Coagulation point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 53. Fertility point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 54. infectious disease point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 55. HIV POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 56. Clostridium Difficile POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 57. HBV POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 58. Pneumonia or streptococcus associated infections point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 59. Respiratory syncytial virus (RSV) POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 60. HPV POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 61. influenza/Flu POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 62. HCV POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 63. MRSA POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 64. TB and drug-resistant TB POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 65. HSV POC diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 66. COVID-19 diagnostics market, 2020 - 2028 (USD Million)
  • 67. Other infectious disease diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 68. Cardiac markers point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 69. Thyroid stimulating hormone point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 70. Hematology point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 71. Primary care systems point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 72. Decentralized clinical chemistry point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 73. Feces point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 74. Lipid testing point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 75. Cancer Marker point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 76. Blood Gas/Electrolytes point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 77. Ambulatory chemistry point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 78. Drug abuse testing point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 79. Urinalysis point of care (PoC) diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
  • 80. Point of Care (PoC) diagnostics market: End-use outlook and key takeaways
  • 81. Point of Care (PoC) diagnostics market: End-use movement analysis
  • 82. Point of Care (PoC) diagnostics market for clinics, 2017 - 2028 (USD Million)
  • 83. Point of Care (PoC) diagnostics market for pharmacy & retail clinics, 2017 - 2028 (USD Million)
  • 84. Point of Care (PoC) diagnostics market for physician office, 2017 - 2028 (USD Million)
  • 85. Point of Care (PoC) diagnostics market for urgent care clinics, 2017 - 2028 (USD Million)
  • 86. Point of Care (PoC) diagnostics market for non-practice clinics, 2017 - 2028 (USD Million)
  • 87. Point of Care (PoC) diagnostics market for hospitals, 2017 - 2028 (USD Million)
  • 88. Point of Care (PoC) diagnostics market for home, 2017 - 2028 (USD Million)
  • 89. Point of Care (PoC) diagnostics market for assisted living healthcare facilities, 2017 - 2028 (USD Million)
  • 90. Point of Care (PoC) diagnostics market for laboratory, 2017 - 2028 (USD Million)
  • 91. Regional market place: Key takeaway
  • 92. POC diagnostics market: Region movement analysis
  • 93. North America point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 94. The U.S. point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 95. Canada point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 96. Europe point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 97. Germany point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 98. The U.K. point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 99. France point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 100. Italy point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 101. Spain point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 102. Russia point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 103. asia Pacific point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 104. Japan point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 105. China point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 106. india point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 107. Australia point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 108. Korea point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 109. Latin America point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 110. Brazil point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 111. Mexico point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 112. Middle East & Africa point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 113. South Africa point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
  • 114. Saudi Arabia point of care (PoC) diagnostics market, 2017 - 2028 (USD Million)
目次
Product Code: 978-1-68038-046-0

Point Of Care Diagnostics & Testing Market Growth & Trends

The global point of care diagnostics & testing market size is estimated to reach USD 35.74 billion by 2028, registering a CAGR of 3.25%, according to a new report by Grand View Research, Inc. Point of care (POC) diagnostics & testing has significantly altered the therapeutic models applied for the treatment of diabetic patients, HIV patients, and patients with Cardiovascular Disorders (CVDs), in recent years. In addition, emerging advancements on the horizon are projected to enhance the near-patient treatment workflows for infectious diseases, strokes, and cancer.

The industry is set to witness lucrative growth as POC testing serves as a profitable alternative to traditional laboratory tests. Point-of-care devices are designed to offer actionable information at the location and time of patient care, which enables early diagnosis of diseases. The advent of non-invasive & minimally invasive POC devices, continuous POCT, miniaturized technologies, and the adoption of telemedicine in remote patient monitoring are some of the key trends contributing to the market growth.

Moreover, the advent of rapid data sharing solutions as well as platforms is set to contribute to the development of POC COVID-19 tests, supplementing the overall market growth. Companies actively working toward the development of such rapid data sharing solutions include Foundation for Innovative New Diagnostics (FIND) and 360 Dx. The rising number of such companies is set to offer manufacturers/developers and professionals a clear perspective with respect to the future opportunities associated with POC COVID-19 tests.

The development of multiplex POC diagnostic technologies that enable the detection of multiple infectious pathogens in specimens, such as sputum, urine, or blood, offers improved patient outcomes and better disease diagnosis. The wide adoption of multiplex POC devices is anticipated to serve as a driver for the shift in preference from a centralized disease testing model to a decentralized patient-centered model.

Major companies are initiating strategic product launches to strengthen their market presence. For instance, in October 2020, Roche announced the launch of the Elecsys SARS-CoV-2 Antigen test that supports COVID-19 testing of suspected patients at high volumes. In April 2020, Nova Biomedical introduced PT/INR testing for its Allegro capillary blood analyzer to be used in POC primary care settings. This test is available in CE-regulated countries.

PR/INR is among the total 18 tests of the Allegro platform and is designed to measure HbA1c, hemoglobin, cholesterol, glucose, triglycerides, UACR, creatinine, hematocrit, and uric acid. This product expanded the testing portfolio of the company's Allergo platform.

Point of Care Diagnostics & Testing Market Report Highlights

The glucose testing product segment led the market in 2020 due to high demand for POC glucose monitors for routine glucose testing as a result of an increased number of diabetic patients across the globe

The infectious disease product segment is expected to account for the highest revenue share by 2028. This growth is majorly attributed to the global COVID-19 pandemic

The first POC diagnostic test for COVID-19 was approved by the U.S. FDA in March 2020 under Emergency Use Authorization, which was manufactured by Cepheid

Since then, key players in this market are engaged in developing and manufacturing such tests, which, in turn, is boosting the segment growth

The clinics end-use segment accounted for the dominant revenue share in 2020 and will expand further at a steady CAGR from 2021 to 2028 owing to increasing transition from conventional lab testing to POCT by healthcare professionals to shorten the time taken for diagnosis and further treatments

Led by the U.S., North America was the leading regional market in 2020 and held a revenue share of more than 34%

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Market Categorization
    • 1.5.2 Point of Care Testing
      • 1.5.2.1 PoC-End-Use Penetration Mapping
    • 1.5.3 Pricing Analysis
    • 1.5.4 Data Analysis Models
  • 1.6 Market formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-Wise Market Estimation Using Bottom Up Approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Market Summary

Chapter 3 Market Variables, Trends, and Scope

  • 3.1 Market Trends and Outlook
  • 3.2 Market Segmentation and Scope
  • 3.3 Parent Market Outlook
    • 3.3.1 Related/Ancillary Market Outlook
      • 3.3.1.1 Molecular Technology intervention
      • 3.3.1.1.1 Key Factors Considered for Analyzing Molecular Technology interventions Across PoC Testing
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 introduction of CLIA Waived Tests
      • 3.4.1.2 Rise in Funding from Government and Private institutions
      • 3.4.1.3 Growing Geriatric Population Base
      • 3.4.1.4 Growing Prevalence of Target Diseases
      • 3.4.1.5 Growing Demand for Home Healthcare and The introduction of Advance Technology Enabled Products
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 High Procedure Costs Coupled with Limited Adoption of PoC Devices in Certain Emerging Regions
      • 3.4.2.2 Presence of Ambiguous Regulatory & Reimbursement Framework for Primary Care Setting
    • 3.4.3 Market Challenge Analysis
      • 3.4.3.1 PoC Devices Pose Challenges in Maintaining The Quality Standards
    • 3.4.4 Market Opportunity Analysis
      • 3.4.4.1 Networking & Remote Access integration of PoC Diagnostics Products
      • 3.4.4.1.1 Smartphone Orientation
      • 3.4.4.1.2 Embedded Vision-Based Solutions
      • 3.4.4.1.3 Digital Technologies
  • 3.5 Penetration and Growth Prospect Mapping for Point of Care Products, 2020
  • 3.6 Swot By Pest Analysis
    • 3.6.1 Political Landscape
    • 3.6.2 Economic Landscape
    • 3.6.3 Social Landscape
    • 3.6.4 Technology Landscape
  • 3.7 Industry Analysis - Porter's
    • 3.7.1 Bargaining Power of Suppliers: Moderate
    • 3.7.2 Bargaining Power of Buyers: Moderate
    • 3.7.3 Threat of Substitution: Low
    • 3.7.4 Threat of New Entrants: Low
    • 3.7.5 Competitive Rivalry: High
  • 3.8 Major Deals & Strategic Alliances Analysis
    • 3.8.1 Joint Ventures
    • 3.8.2 Mergers & Acquisitions
    • 3.8.3 Licensing & Partnership
  • 3.9 Market Entry Strategies
  • 3.10 Price-Cost-Margin Analysis for Point of Care Testing
  • 3.11 User Perspective Analysis
    • 3.11.1 Consumer Behavior Analysis
  • 3.12 Technology Overview
  • 3.13 PoC Diagnostics: Market influencers
    • 3.13.1 High Sensitivity
    • 3.13.2 Shift To Molecular Diagnostics
  • 3.14 Product Positioning Analysis, 2020
    • 3.14.1 Glucose Testing
    • 3.14.2 Hb1Ac Testing
    • 3.14.3 Coagulation Testing
    • 3.14.4 Fertility
    • 3.14.5 Infectious Disease
    • 3.14.6 Cardiac Markers
    • 3.14.7 Thyroid
    • 3.14.8 Hematology
    • 3.14.9 Primary Care
    • 3.14.10 Decentralized Clinical Chemistry
    • 3.14.11 Faecal
    • 3.14.12 Lipid Testing
    • 3.14.13 Cancer Marker
    • 3.14.14 Blood Gas/Electrolytes
    • 3.14.15 Ambulatory Chemistry
    • 3.14.16 Drug of Abuse (Doa) Testing
    • 3.14.17 Urinalysis
  • 3.15 Regulatory Framework Analysis for U.S. Point of Care Diagnostics
  • 3.16 Regulatory Framework Analysis for Europe Point of Care Diagnostics
  • 3.17 Regulatory Framework Analysis for Japan Point of Care Diagnostics

Chapter 4 COVID-19 Impact Analysis

  • 4.1 Overview
    • 4.1.1 COVID-19 Point of Care Diagnostics: Technology Overview
    • 4.1.2 COVID-19 Point of Care Diagnostics: Regulatory Overview
    • 4.1.3 COVID-19 Point of Care Diagnostics: Competitive Landscape

Chapter 5 Competitive Analysis

  • 5.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2 Company/Competition Categorization
  • 5.3 Vendor Landscape
    • 5.3.1 Key Distributors Marketing Channels
      • 5.3.1.1 Abbott Diagnostics
      • 5.3.1.1.1 Abbott Diagnostics: Marketing Channels & Distribution Network for PoC
      • 5.3.1.1.2 Alere Inc.
      • 5.3.1.1.2.1 Alere: Marketing Channels & Distribution Network for PoC
      • 5.3.1.2 Roche Diagnostics
      • 5.3.1.2.1 Roche Diagnostics: Marketing Channels & Distribution Network for PoC
      • 5.3.1.3 Siemens Healthcare
      • 5.3.1.3.1 Siemens Healthcare: Marketing Channels & Distribution Network for PoC
      • 5.3.1.4 Danaher Corporation
      • 5.3.1.4.1 Danaher Corporation: Marketing Channels & Distribution Network for PoC
      • 5.3.1.5 instrumentation Laboratory SpA.
      • 5.3.1.5.1 instrumentation Laboratory SpA.: Marketing Channels & Distribution Network for PoC
      • 5.3.1.6 Becton Dickinson
      • 5.3.1.6.1 Becton Dickinson.: Marketing Channels & Distribution Network for PoC
    • 5.3.2 Key Customers
  • 5.4 Key Company Market Ranking, 2020
    • 5.4.1 Company Size
    • 5.4.2 Distribution Network
    • 5.4.3 Product Portfolio
    • 5.4.4 Segment Coverage
    • 5.4.5 Geographic Presence
    • 5.4.6 Collaborations
    • 5.4.7 Conclusion
  • 5.5 Public Companies
    • 5.5.1 Number of Products
    • 5.5.2 Market Penetration
    • 5.5.3 Strategic Initiatives
    • 5.5.4 Segment Coverage
    • 5.5.5 Geographical Presence
    • 5.5.6 Competitive Dashboard Analysis
  • 5.6 Market Differentiators
    • 5.6.1 Application Trends
    • 5.6.2 Technology Trends
    • 5.6.3 Test Location Trends
    • 5.6.4 End-Use Trends
    • 5.6.5 Regional Trends
  • 5.7 Private Companies
    • 5.7.1 New Entrants/Emerging Players
  • 5.8 Regional Mapping: Public and Private Companies

Chapter 6 Product Business Analysis

  • 6.1 Point of Care (PoC) Diagnostics & Testing Market: Product Movement Analysis
    • 6.1.1 Glucose Testing
      • 6.1.1.1 Glucose Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.2 Hb1ac Testing
      • 6.1.2.1 Hb1Ac Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.3 Coagulation
      • 6.1.3.1 Coagulation Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.4 Fertility
      • 6.1.4.1 Fertility Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.5 Infectious Diseases
      • 6.1.5.1 Infectious Disease Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.2 HIV PoC
      • 6.1.5.2.1 HIV PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.3 Clostridium Difficile PoC
      • 6.1.5.3.1 Clostridium Difficile PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.4 HBV PoC
      • 6.1.5.4.1 HBV PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.5 Pneumonia Or Streptococcus Associated Infections
      • 6.1.5.5.1 Pneumonia Or Streptococcus associated infections Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.6 Respiratory Syncytial Virus (RSV) PoC
      • 6.1.5.6.1 Respiratory Syncytial Virus (Rsv) PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.7 HPV PoC
      • 6.1.5.7.1 HPV PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.8 Influenza/Flu PoC
      • 6.1.5.8.1 Influenza/Flu PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.9 HCV PoC
      • 6.1.5.9.1 HCV PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.10 MRSA PoC
      • 6.1.5.10.1 MRSA PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.11 TB and Drug-Resistant TB PoC
      • 6.1.5.11.1 TB and Drug-Resistant TB PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.12 HSV PoC
      • 6.1.5.12.1 HSV PoC Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.13 COVID-19
      • 6.1.5.13.1 COVID-19 Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
      • 6.1.5.14 Other Infectious Diseases
      • 6.1.5.14.1 Other infectious Disease Diagnostics Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.6 Cardiac Markers
      • 6.1.6.1 Cardiac Markers Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.7 Thyroid Stimulating Hormone
      • 6.1.7.1 Thyroid Stimulating Hormone Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.8 Hematology
      • 6.1.8.1 Hematology Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.9 Primary Care Systems
      • 6.1.9.1 Primary Care Systems Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.10 Decentralized Clinical Chemistry
      • 6.1.10.1 Decentralized Clinical Chemistry Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.11 Feces
      • 6.1.11.1 Feces Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.12 Lipid Testing
      • 6.1.12.1 Lipid Testing Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.13 Cancer Marker
      • 6.1.13.1 Cancer Marker Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.14 Blood Gas/Electrolytes
      • 6.1.14.1 Blood Gas/Electrolytes Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.15 Ambulatory Chemistry
      • 6.1.15.1 Ambulatory Chemistry Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.16 Drug Abuse Testing
      • 6.1.16.1 Drug Abuse Testing Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 6.1.17 Urinalysis
      • 6.1.17.1 Urinalysis Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, 2017 - 2028 (USD Million)

Chapter 7 End-Use Business Analysis

  • 7.1 Point of Care (PoC) Diagnostics & Testing Market: End-Use Movement Analysis
    • 7.1.1 Clinics
      • 7.1.1.1 Point of Care (PoC) Diagnostics & Testing Market for Clinics, 2017 - 2028 (USD Million)
      • 7.1.1.2 Pharmacy & Retail Clinics
      • 7.1.1.2.1 Point of Care (PoC) Diagnostics & Testing Market for Pharmacy & Retail Clinics, 2017 - 2028 (USD Million)
      • 7.1.1.3 Physician Office
      • 7.1.1.3.1 Point of Care (PoC) Diagnostics & Testing Market for Physician office, 2017 - 2028 (USD Million)
      • 7.1.1.4 Urgent Care Clinics
      • 7.1.1.4.1 Point of Care (PoC) Diagnostics & Testing Market for Urgent Care Clinics, 2017 - 2028 (USD Million)
      • 7.1.1.5 Non-Practice Clinics
      • 7.1.1.5.1 Point of Care (PoC) Diagnostics & Testing Market for Non-Practice Clinics, 2017 - 2028 (USD Million)
    • 7.1.2 Hospitals
      • 7.1.2.1 Point of Care (PoC) Diagnostics & Testing Market for Hospitals, 2017 - 2028 (USD Million)
    • 7.1.3 Home
      • 7.1.3.1 Point of Care (PoC) Diagnostics & Testing Market for Home, 2017 - 2028 (USD Million)
    • 7.1.4 Assisted Living Healthcare Facilities
      • 7.1.4.1 Point of Care (PoC) Diagnostics & Testing Market for assisted Living Healthcare Facilities, 2017 - 2028 (USD Million)
    • 7.1.5 Laboratory
      • 7.1.5.1 Point of Care (PoC) Diagnostics & Testing Market for Laboratory, 2017 - 2028 (USD Million)

Chapter 8 Region Business Analysis

  • 8.1 Point of Care (PoC) Diagnostics & Testing Market: Regional Movement Analysis, 2020 & 2028
  • 8.2 North America
    • 8.2.1 North America Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By Product, 2017 - 2028 (USD Million)
    • 8.2.2 North America Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By End Use, 2017 - 2028 (USD Million)
    • 8.2.3 The U.S.
      • 8.2.3.1 The U.S. Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.2.4 Canada
      • 8.2.4.1 Canada Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By Product, 2017 - 2028 (USD Million)
    • 8.3.2 Europe Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By End Use, 2017 - 2028 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Germany Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.3.4 The U.K.
      • 8.3.4.1 The U.K. Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.3.5 France
      • 8.3.5.1 France Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.3.6 Italy
      • 8.3.6.1 Italy Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.3.7 Spain
      • 8.3.7.1 Spain Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.3.8 Russia
      • 8.3.8.1 Russia Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By Product, 2017 - 2028 (USD Million)
    • 8.4.2 Asia Pacific Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By End Use, 2017 - 2028 (USD Million)
    • 8.4.3 Japan
      • 8.4.3.1 Japan Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.4.4 China
      • 8.4.4.1 China Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.4.5 India
      • 8.4.5.1 India Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.4.6 Australia
      • 8.4.6.1 Australia Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.4.7 Korea
      • 8.4.7.1 Korea Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By Product, 2017 - 2028 (USD Million)
    • 8.5.2 Latin America Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By End Use, 2017 - 2028 (USD Million)
    • 8.5.3 Brazil
      • 8.5.3.1 Brazil Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.5.4 Mexico
      • 8.5.4.1 Mexico Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
  • 8.6 Middle East & Africa (Mea)
    • 8.6.1 Middle East & Africa Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By Product, 2017 - 2028 (USD Million)
    • 8.6.2 Middle East & Africa Point of Care (PoC) Diagnostics & Testing Market Estimates and Forecast, By End Use, 2017 - 2028 (USD Million)
    • 8.6.3 South Africa
      • 8.6.3.1 South Africa Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)
    • 8.6.4 Saudi Arabia
      • 8.6.4.1 Saudi Arabia Point of Care (PoC) Diagnostics & Testing Market, 2017 - 2028 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Company Profiles
    • 9.1.1 F. Hoffmann-La Roche Ltd.
      • 9.1.1.1 Company Overview
      • 9.1.1.2 Financial Performance
      • 9.1.1.3 Product Benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.2 Qiagen
      • 9.1.2.1 Company Overview
      • 9.1.2.2 Financial Performance
      • 9.1.2.3 Product Benchmarking
      • 9.1.2.4 Strategic initiatives
    • 9.1.3 Danaher Corporation
      • 9.1.3.1 Company Overview
      • 9.1.3.2 Beckman Coulter, Inc.
      • 9.1.3.2.1 Company Overview
      • 9.1.3.2.2 Radiometer Medical Aps
      • 9.1.3.2.3 Hemocue Ab
      • 9.1.3.3 Financial Performance
      • 9.1.3.4 Product Benchmarking
      • 9.1.3.5 Strategic Initiatives
    • 9.1.4 Becton Dickinson (BD)
      • 9.1.4.1 Company Overview
      • 9.1.4.2 Financial Performance
      • 9.1.4.3 Product Benchmarking
      • 9.1.4.4 Strategic Initiatives
    • 9.1.5 Biomerieux SA
      • 9.1.5.1 Company Overview
      • 9.1.5.2 Financial Performance
      • 9.1.5.3 Product Benchmarking
      • 9.1.5.4 Strategic Initiatives
    • 9.1.6 Abbott Laboratories
      • 9.1.6.1 Company Overview
      • 9.1.6.2 Alere, inc.
      • 9.1.6.2.1 Company Overview
      • 9.1.6.3 Financial Performance
      • 9.1.6.4 Product Benchmarking
      • 9.1.6.5 Strategic Initiatives
      • 9.1.6.5.1 Strategic initiatives (Alere)
    • 9.1.7 Siemens Healthcare AG
      • 9.1.7.1 Company Overview
      • 9.1.7.2 Financial Performance
      • 9.1.7.3 Product Benchmarking
      • 9.1.7.4 Strategic Initiatives
    • 9.1.8 Zoetis, Inc.
      • 9.1.8.1 Company Overview
      • 9.1.8.2 Abaxis
      • 9.1.8.3 Company Overview
      • 9.1.8.4 Financial Performance
      • 9.1.8.4.1 Financial Performance (Abaxis)
      • 9.1.8.5 Product Benchmarking
      • 9.1.8.6 Strategic Initiatives
    • 9.1.9 Instrumentation Laboratory
      • 9.1.9.1 Company Overview
      • 9.1.9.2 Accriva Diagnostics
      • 9.1.9.2.1 Company Overview
      • 9.1.9.3 International Technidyne Corporation (ITC)
      • 9.1.9.3.1 Company Overview
      • 9.1.9.4 Financial Performance (Instrumentation Laboratory)
      • 9.1.9.4.1 Financial Performance (International Technidyne)
      • 9.1.9.5 Product Benchmarking
      • 9.1.9.6 Strategic Initiatives
    • 9.1.10 Nova Biomedical
      • 9.1.10.1 Company Overview
      • 9.1.10.2 Financial Performance
      • 9.1.10.3 Product Benchmarking
      • 9.1.10.4 Strategic initiatives
    • 9.1.11 Trividia Health, Inc.
      • 9.1.11.1 Company Overview
      • 9.1.11.2 Financial Performance
      • 9.1.11.3 Product Benchmarking
      • 9.1.11.4 Strategic Initiatives
    • 9.1.12 Quidel Corporation
      • 9.1.12.1 Company Overview
      • 9.1.12.2 Financial Performance
      • 9.1.12.3 Product Benchmarking
      • 9.1.12.4 Strategic initiatives
    • 9.1.13 Trinity Biotech
      • 9.1.13.1 Company Overview
      • 9.1.13.2 Financial Performance
      • 9.1.13.3 Product Benchmarking
      • 9.1.13.4 Strategic Initiatives
    • 9.1.14 Sekisui Diagnostics
      • 9.1.14.1 Company Overview
      • 9.1.14.2 Product Benchmarking
      • 9.1.14.3 Strategic Initiatives
    • 9.1.15 Orasure Technologies, Inc.
      • 9.1.15.1 Company Overview
      • 9.1.15.2 Financial Performance
      • 9.1.15.3 Product Benchmarking
      • 9.1.15.4 Strategic Initiatives
    • 9.1.16 Nipro Corp.
      • 9.1.16.1 Company Overview
      • 9.1.16.2 Financial Performance
      • 9.1.16.3 Product Benchmarking
    • 9.1.17 Spectral Medical, Inc.
      • 9.1.17.1 Company Overview
      • 9.1.17.2 Financial Performance
      • 9.1.17.3 Product Benchmarking
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.